Joint Broker Appointment

RNS Number : 9262X

ValiRx PLC

30 June 2008

 



30 June 2008

ValiRx plc

Appointment of Joint Broker

ValiRx plc (AIM:VAL, 'the Company'), the cancer therapeutics and diagnostics company, has appointed Old Park Lane Capital plc as the Company's Joint Broker to work with the Company's Nominated Adviser and Joint Broker, WH Ireland Limited, with immediate effect. 

Enquiries

ValiRx plc	Tel: [phone]
Dr Satu Vainikka, CEO
WH Ireland Limited - Nominated Adviser & Joint Broker	Tel: [phone]
David Youngman / Adrian Kirk
Old Park Lane Capital plc - Joint Broker	Tel: [phone]
Michael Parnes
College Hill	Tel:  [phone]
Adrian Duffield/Justine Lamond
[e-mail]

Note to Editors

About ValiRx
ValiRx plc (AIM:VAL, 'ValiRx') is a cancer therapeutics and diagnostics company headquartered in London, England and admitted to AIM in October 2006. The Company operates through two subsidiaries, Cronos Therapeutics Ltd (www.cronostherapeutics.com), a UK-based epigenetic drug discovery and development business and ValiBIO SA (www.valibio.com), a Belgium-based oncology diagnostics operation.

Therapeutics - Cronos Therapeutics Ltd
ValiRx utilises a cells own inherent gene control machinery to silence genes involved in cancer cell progression, effectively 'switching off' genes involved in certain forms of cancer through its platform technology GeneICE™ (Gene Inactivation by Chromatin Engineering),. GeneICE™ works through the recruitment of silencing complexes known as Histone Deacetylase Complexes (HDACs) to target genes involved in cancer. ValiRx's lead product VAL 101 targets the anti-apoptotic gene BCL-2 which is over expressed in many cancers including in pancreatic cancer. 

Gene silencing technology platform potentially represents an innovative and ground breaking new approach to cancer treatment as it allows for the development of targeted, personalised medicine and treatment for patients. GeneICE™ is also applicable to a wide variety of other genetic disorders such as in the fields of neurology and inflammatory diseases. 

Diagnostics - ValiBIO SA 
ValiRx currently has two epigenetic diagnosis products - HyperGenomicsTM, a method for the detection and identification of hypersensitive sites in cells and NucleosomicsTM, a non-invasive (blood) test for early cancer diagnosis based on epigenetic signal changes associated with malignancy - which it licences to its subsidiary, ValiBIO. 

More information on the Company can be found at www.valirx.com

Epigenetics

Epigenetics is the study and manipulation of regulatory factors which regulate and determine gene expression. 

Unlike mutations which occur in DNA, epigenetic changes are reversible. The 'epigenetic' modification of the genome may take many forms, such as addition of external chemical groups for example methylation, acetylation and ubiquitination on to histone proteins associated with DNA. 

Research currently suggests the de-regulation of normal epigenetic control mechanisms is implicated in the development and progression of certain cancers. Hence, compounds which specifically target and reverse these changes are attractive and potentially powerful candidates for future therapeutic approaches to cancer.

Personalised medicine

Personalised medicine refers to tailoring treatment strategies to work differently in different individuals, dependant upon such factors such as their genetic profile, epigenetic profile, environment and the presence of other diseases in the individual.

 

END

 

 

APPILFVERVIIVIT